Tumor Mutation Burden and Checkpoint Immunotherapy Markers in NUT Midline Carcinoma

Keyphrases

• Programmed Death-ligand 1 (PD-L1) 100%
• Tumor mutation Burden 100%
• Checkpoint Immunotherapy 100%
• NUT Midline Carcinoma 100%
• Tumor mutational Burden 80%
• Whole Exome Sequencing 60%
• High-power Field 60%
• CD-8 40%
• Tumor 20%
• Fluorescence in Situ Hybridization 20%
• Primary Tumor 20%
• Young Female 20%
• Young Males 20%
• Pulmonary Metastasis 20%
• Gene Rearrangement 20%
• Immunohistochemical Markers 20%
• Mismatch Repair 20%
• Poorly Differentiated Carcinoma 20%
• Checkpoint Therapy 20%
• DNA Mismatch Repair Protein 20%
• Tumor Proportion Score 20%
• CD8 Count 20%
• Combined Positive Score 20%
• NUTM1 20%

Medicine and Dentistry

• Immunotherapy 100%
• Tumor Mutation Burden 100%
• NUT Midline Carcinoma 100%
• Programmed Cell Death 100%
• Tumor Mutational Burden 100%
• CD8 Antigen 75%
• Exome Sequencing 75%
• Neoplasm 50%
• DNA Mismatch Repair 50%
• Biological Marker 25%
• Fluorescence in Situ Hybridization 25%
• Primary Tumor 25%
• Carcinoma 25%
• Programmed Death 1 Ligand 1 25%
• Lung Metastasis 25%
• Gene Rearrangement 25%
• Mismatch Repair Protein 25%

Biochemistry, Genetics and Molecular Biology

• Exome Sequencing 100%
• Programmed Cell Death 1 100%
• Cell Death 66%
• CD8 66%
• DNA Mismatch Repair 66%
• Fluorescence in Situ Hybridization 33%
• Gene Rearrangement 33%
• CD8 Lymphocyte Count 33%